Pulmonary Function (PF) After Stem Cell Transplant (SCT) Is Significantly Better in Children and Adolescents Who Receive Reduced Toxicity Conditioning (RTC) Versus Myeloablative Conditioning (MAC) and Significantly Decreased in Those Who Develop Chronic GVHD (cGVHD)  by Majzner, R. et al.
Table 1. Patient Characteristics
Patient Diagnosis
Donor
Source Virus
Days of
CMX001
treatment
Neutrophil
Engraftment Dose of CMX001 % Donor Engraftment
1 SCID MUD ADV +11 to +54 +13 4 mg/kg/dose BIW 100
2 MDS with
Monosomy 7
MSD CMV +2 to +39 +11 4 mg/kg/dose BIW for 6 doses then 2 mg/kg/
dose BIW x 4 doses
100
3 Autoimmune
neutropenia
and Hepatitis
MUD CMV +3 to +30 +13 4 mg/kg/dose BIW x 7 doses then 4 mg/kg/dose
QW for 1 dose
0
4 XLP MUD HHV6 -48 to +7 +11 2 mg/kg/dose BIW 100
SCID: Severe Combined Immunodeficiency; MDS: Myelodysplastic Syndrome; XLP: X-Linked Lymphoproliferative Disorder; HHV6: Human Herpes
Virus -6; Neutrophil Engraftment: Day post HSCTANC > 500; BIW: twice a week; QW: weekly.
Poster Session I S317undetectable viral DNA in blood. Patient characteristics are shown
in Table 1.
Results:No hematologic toxicity from CMX001 was observed with
prompt neutrophil engraftment in all patients. The patient with au-
tologous recovery was considered to be at very high risk for graft re-
jection secondary to his diagnosis. No adverse events attributable to
CMX001 were seen with either the 4 mg/kg/dose or 2 mg/kg/dose
twice weekly dosing. Three of four patients had a. 1 log drop in vi-
ral load at the end of 1 week of therapy. VR was seen in 3/4 patients
with amedian time to achieve VR of 2 weeks (range 1-3). The patient
who did not have a VR had a.75% decrease in viral load by the end
of week 1 of treatment that was sustained throughout the 6 weeks of
CMX001 treatment.
Discussion: Though a small number of patients were treated, a fa-
vorable safety profile was observed in these patients with no evidence
of delayed hematologic engraftment attributed to CMX001. Four
patients received doses exceeding those currently being studied.
CMX001 is a promising therapy for potential use prior to engraft-
ment in HSCT recipients. Further investigation to confirm the
safety of CMX001 prior to engraftment in HSCT recipients is war-
ranted.300
DISCERNING POST HSCT IMMUNE RESPONSE TO THE INFLUENZA VAC-
CINE AND METHODS TO IMPROVE VACCINE EFFICACY
Karras, N.A.1, Verneris, M.R.1, DeFor, T.E.1, Sessions, W.M.2, Xu, X.2,
Klimov, A.2 1University of Minnesota, Minneapolis, MN; 2Centers for
Disease Control, Atlanta, GA
Influenza infections following hematopoietic stem cell transplan-
tation (HSCT) are potentially life threatening.While newer antiviral
medications may reduce influenza morbidity, the ideal preventative
strategy is unknown in post-HSCT patients. Prior studies demon-
strate that a single influenza vaccine is relatively ineffective at induc-
ing influenza specific immunity, especially early after HSCT. We
hypothesized that a second vaccine dose, as is standard of care in vac-
cine na€ıve pediatric patients, might improve vaccine efficacy post-
HSCT. During the 2010 influenza season, we conducted a clinical
trial with patients who were.60 days post HSCT, and randomized
them to receive either 1 (n5 30) or 2 (n5 32) flu vaccines separated
by one month. Blood samples were obtained pre-vaccination, 4
weeks and 8 weeks after the first vaccine for hemagglutination and
IFN-g ELISPOT testing. Of the 62 patients, 45 were.18 yrs, 24 re-
ceived non-myeloablative conditioning and 22 were umbilical cord
blood transplant recipients. Hemagglutination responses to the
2010/2011 vaccine components (H3N2, H1N1 and B/Victoria)
were significantly greater for patients vaccinated$1 year post trans-
plant (p\5 0.005 for all 3 strains) compared to those vaccinated at
earlier time points. Testing of T cell specific responses is ongoing,
but week 8 ELISPOT samples show that 7/15 tested patient samples
had IFN-g vaccine specific responses (defined as.10x increase over
baseline). Interestingly, we observed influenza specific T cell re-
sponses in patients without recognizable antibody responses
(n 5 4/15). Vaccine specific T cell responses were observed in 2/8
patients\1 yr post-HSCT and 5/7 .1 yr post-HSCT. Recipientsof 2 vaccines did not show a significant improvement in hemaggluti-
nation responses. This study shows that in some cases vaccinating
before the recommended 6 months post HSCT may be beneficial
sinceT cell responses can be induced. Analysis is ongoing with hopes
to delineate T cell vaccine response relationships between the two
cohorts and the various stem cell sources.301
PULMONARY FUNCTION (PF) AFTER STEM CELL TRANSPLANT (SCT) IS
SIGNIFICANTLY BETTER IN CHILDREN AND ADOLESCENTS WHO RE-
CEIVE REDUCED TOXICITY CONDITIONING (RTC) VERSUS MYELOABLA-
TIVE CONDITIONING (MAC) AND SIGNIFICANTLY DECREASED IN THOSE
WHO DEVELOP CHRONIC GVHD (CGVHD)
Majzner, R.1, Jin, Z.2, Van de Ven, C.3, Duffy, D.3, Dalal, R.1, Ricci, A.1,
Radhakrishnan, K.1, Harrison, L.3, Cairo, M.S.3 1Columbia University,
New York, NY; 2Columbia University, New York, NY; 3New York Med-
ical College, Valhalla, NY
Background: Deterioration in PF after MAC and SCT has previ-
ously been reported in pediatric recipients (Fanfulla et al., ERJ,
1997). RTC has been associated with decreased systemic complica-
tions following SCT (Satwani/Cairo, BBMT, 2005).
Objectives: To determine in a multivariate analysis the risk factors
associated with PF deterioration in pediatric recipients following
SCT.
Design/Method: All patients who underwent SCT under IRB ap-
proved studies were analyzed for PF by standard methods. Reliable
spirometry results pre-SCT and 1-2 years post-SCT were analyzed
on forty recipients, lung volume on twenty-six patients, and diffusion
capacity on thirty-five patients. Pre and post-SCT results were com-
pared using paired t-test analysis. Univariate sub-group analysis was
carried out using the unpaired t-test on the post-SCT results to de-
termine which variables contribute to PF deterioration. All variables
with a p-value less than 0.2 in univariate analysis were included in
a multivariate regression analysis.
Results:M/F 27/13, median age 13 years (5 to 21), malignant/non-
malignant 26/14, and RTC/MAC 26/14. Forced Vital Capacity
(FVC), Forced Expiratory Volume in 1-second (FEV1), Total
LungCapacity (TLC), andDiffusion Capacity (DLCO) were all sig-
nificantly reduced after transplant (Table 1). FEV1/FVC values were
not significantly different before and after SCT.
Sub-group analysis revealed worse PF in patients who underwent
MAC (FVC 71.36 5.3%, FEV1 72.76 4.8%, TLC 74.96 6.4%) as
compared with those who underwent RTC (FVC 80.4 6 2.6%,
FEV1 83.2 6 3.5%, TLC 90.4 6 4.0%) (p 5 0.045, 0.044, and
0.021 respectively). Additionally, patients with cGVHD had signifi-
cantly reduced FVC (68.1 6 4.3% v 81.1 6 2.9%, p 5 0.009) and
FEV1 (72.26 5.6% v 82.66 3.3%, p5 0.05) when compared to pa-
tients without cGVHD.
In multivariate logistic regression, undergoing RTC vs MAC was
an independent, significant predictor of greater post-SCT TLC
(p5 0.046). Additionally, development of cGVHD was an indepen-
dent, significant predictor for reduced FVC post-transplant
(p 5 0.047).
S318 Poster Session IConclusion:Children and adolescents who undergo RTC appear to
have significantly better PF outcomes one to two years after SCT
versus those undergoingMAC. Development of cGVHD is a signif-
icant predictor of PF deterioration.
Table 1. Pulmonary Function Testing Before and After SCT
Pre-SCT Mean Post-SCT Mean
N (%-predicted) (%-predicted) p-valueFVC 40 85.5±2.4% 77.2±2.6% <0.0001
FEV1 40 88.7±3.0% 79.5±2.9% <0.0001
TLC 26 92.7±3.3% 85.0±3.7% 0.012
DLCO 35 72.6±3.3% 66.0±3.3% 0.033
FEV1/FVC 40 102.8±1.6% 103.1±1.5% 0.837302
THE FREQUENCY OF INTERVAL SURVEILLANCE IN THE ADULT HEMATO-
POIETIC STEM CELL TRANSPLANT SURVIVOR
Beavers-Kirby, J.R.1, McDaniel, J.2, Barker, E.2, Lester, J.1,2,
Warren, B.2 1The Ohio State University James Cancer Hospital and So-
love Research Institute, Columbus, OH; 2The Ohio State University, Co-
lumbus, OH
Cancer treatments for hematologic malignancies can include radi-
ation, chemotherapy, immunosuppression, stem cell transplant, and
targeted biological therapies. These therapies can cause long-term
side effects that may negatively affect quality of life. This plan is
most effective when factors such as past treatments, chromosomal
prognostic factors, comorbid health conditions, and lifestyle behav-
iors are considered.
A survivorship care plan specific for cancer survivors who have un-
dergone a hematopoietic stem cell transplant (HSCT) would en-
hance the ability of clinicians to monitor for late effects. The
Center for International Blood and Marrow Transplant Research,
the European Group for Blood and Marrow Transplantation, and
the American Society for Blood and Marrow Transplant have re-
commended that a HSCT-specific survivorship care plan include
6-month, 12-month, and annual assessments of physical and psycho-
social well-being including preventive screenings unique to the
HSCT survivor.
The purpose of this quality improvement study was to describe the
frequency of documentation of the recommended cancer survivor-
ship guidelines by oncology clinicians in the medical records of adult
HSCT survivors at 12 and 24months post-transplant in one compre-
hensive cancer center. This retrospective chart reviewwas conducted
over 2 years. Charts were selected based on length of time since
HSCT. Over 300 charts were included in this study. Only 3 of the
29 recommended guidelines were documented as being completed
in more than 50% of the charts at 12 and 24 months. These 3 indi-
cators included aggressive management of blood pressure, serum
blood urea nitrogen and creatinine and serum liver function testing.
There were 2 additional indicators which were documented as com-
pleted in more than 50% of the charts at 12 months post HSCT, but
less than 50% of the charts at 24 months post HSCT. These indica-
tors were ‘consideration of herpes simplex virus and antifungal pro-
phylaxis’ and ‘pneumocystis carinii pneumonia prophylaxis.’
Additionally, the data indicated that the remaining indicators were
documented in less than 50% of the charts at both 12 and 24months.
These findings were used to inform the oncology clinicians of the
need for adherence to recommended guidelines and in the planning
of a hematology and transplant survivorship clinic for individuals
who have completed the acute phase of their cancer treatment.
Table. Treatment Summary
Diagnosis:
Date of diagnosis Age at diagnosis Date therapy complete
Prognostic features CytogeneticsSummary of treatment:
Treatment Center(s):
Past Medical History
Problem Ongoing Therapy(Continued )Table. (Continued )
Diagnosis:
Date of diagnosis Age at diagnosis Date therapy complete
Prognostic features CytogeneticsSummary of treatment:
Treatment Center(s):
Past Medical History
Problem Ongoing TherapyRelapse
Date Site TherapySecondary Malignancy
Date Site TherapyProtocol(s)
Acronym/Number Therapy and datesChemotherapy
Date(s) Drug Name/Route Total doseRadiation
Type/Site Date Dose per fraction/Total DoseSurgery
Date Procedure Institute/SurgeonTransfusion History
Transfusion Reaction Pre Medication
Adverse Drug Reactions/Allergies
Drug ReactionHemtopoietic Stem Cell Transplant
Date of Transplant:
Autologous or Allogeneic:
Donor Source: Peripheral/Marrow/Umbilical Cord
HLA Match:
ABO Match:
Sex Match:
Conditioning Regimen:
Cell Dose:
Transplant Physician:
Institution:
Graft versus Host Disease
Organs Involved:
GVHD Grade:
Severity: Mild/Moderate/Extensive
GVHD Treatment SummaryDrug Start Date Stop Date
HSCT Complications/Late EffectsProblem Dates Ongoing Therapy303
A SNAPSHOT OF MY LIFE: PHOTOVOICE PHOTOGRAPHY PROJECT
Schmid, C.L.1, Donnelly, M.M.1, Davies, S.M.1, Vaughn, L.M.2 1Cin-
cinnati Children’s Hospital Medical Center, Cincinnati, OH; 2Cincinnati
Children’s Hospital Medical Center, Cincinnati, OH
The Bone Marrow Transplant Unit in the Cancer and Blood Dis-
eases Institute is a place of hope for many patients and families im-
pacted with diseases ranging from cancer, bone marrow failure to
immunology disorders. When most other treatments have failed,
and bone marrow transplant is a viable option, the families will typ-
ically proceed with this treatment. What follows is a prolonged hos-
pitalization with an even greater length of follow-up. The need to
address the patients’ and families’ psychological well-being and cop-
ing strategies becomes a priority during such an extended inpatient
stay, and finding creative ways to do so can be challenging. Through
this concern, A Snapshot of My Life: Photovoice Photography Project was
developed to support patients in processing and sharing their feel-
ings and experiences. Patients, ages five to 23 were loaned digital
cameras to record days in their lives on the BMT unit. During the
review of photos, social workers interacted with the patient to elicit
feelings connected to the photos, creating a therapeutic environment
for the patient and family. This presentation will discuss the Photo-
voice demonstration project on a pediatric bone marrow transplant
unit from inception to implementation. The impact on the patient,
relationship between patient and caregiver, and the influence of
the project on the medical team and therapeutic relationships will
be shared. As a result of the project, a deeper understanding of the
emotional impact a bone marrow transplant and subsequent treat-
ment has on patients was gained. In addition, the therapeutic
